Table 4.

Comparison of demographic and treatment characteristics

	GT1 patients		GT3 patients
	IFN-based treatment (n=17)	IFN-free treatment (SOF + LDV)a (n=100)	IFN-based treatment (n=10)	IFN-free treatment (SOF + DCV)b (n=100)
Demographics
Genotype, %
1a	53	67	N/A	N/A
1b	41	31	N/A	N/A
Unconfirmed	6	2	N/A	N/A
Male, %	53	59	60	57
Mean BMI	28	27	26	27
Cirrhosis, %	24	16	10	19
Treatment
Treatment duration (weeks), mean ± SD	32.9 ± 11.6	12.0 ± 0	33.4 ±12.15	14.28 ± 4.7

Notes:

^aDerived from ION-I trial (Afdhal et al¹⁸).

^bDerived from ALLY-3 trial (Nelson et al¹⁹).

Abbreviations: BMI, body mass index; DCV, daclatasvir; GT1, genotype 1; GT3, genotype 3; IFN, interferon; LDV, ledipasvir; N/A, not applicable; SD, standard deviation; SOF, sofosbuvir.